Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found ...

The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...

After visiting his GP, he was referred to hospital for further testing, where he said he had to push for “progress and ...

Cancer treatment has come a long way, but many of today's therapies still come with steep costs: not just financial, but ...

Fifteen-year-old Isabella Harris has a lot going for her. She’s a talented dancer and a dedicated student, but right now ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer ...

Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...

The drug pazopanib (Votrient) extended the lives of a small group of kids with Ewing sarcoma, which causes cancerous tumors ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase ...